Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Utilizing antibody-drug conjugates in the treatment of metastatic urothelial carcinoma

Arlene O. Siefker-Radtke • 20 Oct 2023
ESMO 2023
Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab vedotin Pembrolizumab Sacituzumab govitecan

Arlene O. Siefker-Radtke, MD, MD Anderson Cancer Center, Houston, TX, discusses the use of antibody-drug conjugates in the treatment of metastatic urothelial carcinoma, elaborating on the possible combination of these immunotherapies in clinical practice to improve treatment outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Arlene O. Siefker-Radtke

3:02
Novel treatment options for patients with metastatic, inoperable urothelial carcinomas
Arlene O. Siefker-Radtke • 20 Oct 2023
3:37
Phase III THOR study: erdafitinib vs. pembrolizumab in FGFR-altered advanced or metastatic UC
Arlene O. Siefker-Radtke • 20 Oct 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals